Protein kinase C inhibitor prevents renal apoptotic and fibrotic changes in response to partial ureteric obstruction

BJU International

Volumn 110, Issue 2, 2012, Pages 283-292

  Juan, Yung Shun ^a,c   Chuang, Shu Mien ^d   Long, Cheng Yu ^a,d   Lin, Rong Jyh ^a   Liu, Keh Min ^b   Wu, Wen Jeng ^a,d   Huang, Chun Hsiung ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Interstitial fibrosis; Kidney; Obstruction; Protein kinase C

Indexed keywords

CHELERYTHRINE; COLLAGEN; CREATININE; FIBRONECTIN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INTERACTION; COLLAGEN DEPOSITION; COLLAGEN METABOLISM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; HYDRONEPHROSIS; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; MALE; MITOSIS INHIBITION; NONHUMAN; PARTIAL URETERIC OBSTRUCTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UREA NITROGEN BLOOD LEVEL; URETER OBSTRUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BENZOPHENANTHRIDINES; FIBRONECTINS; FIBROSIS; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY GLOMERULUS; KIDNEY PELVIS; KIDNEY TUBULES; MALE; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA; URETERAL OBSTRUCTION;

EID: 84863490758     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10805.x     Document Type: Article

References (40)

1. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 2002; 283: F861-75 (Pubitemid 35192452)
2. Klahr S, Morrissey JJ. The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Semin Nephrol 1998; 18: 622-32 (Pubitemid 28506734)
3. Palmieri PA. Obstructive nephropathy: pathophysiology, diagnosis, and collaborative management. Nephrol Nurs J 2002; 29: 15-21, 96; quiz 22-3
4. Liu JP. Protein kinase C and its substrates. Mol Cell Endocrinol 1996; 116: 1-29
5. Hug H, Sarre TF. Protein kinase C isoenzymes: divergence in signal transduction? Biochem J 1993; 2 91: 329-43 (Pubitemid 23127010)
6. Zhang L, Ma J, Gu Y, Lin S. Effects of blocking the renin-angiotensin system on expression and translocation of protein kinase C isoforms in the kidney of diabetic rats. Nephron Exp Nephrol 2006; 104: e103-11 (Pubitemid 44580365)
7. Tossidou I, Starker G, Kruger J et al. PKC-alpha modulates TGF-beta signaling and impairs podocyte survival. Cell Physiol Biochem 2009; 24: 627-34
8. Kelly DJ, Zhang Y, Hepper C et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003; 52: 512-8 (Pubitemid 36173211)
9. Joy SV, Scates AC, Bearelly S et al. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. Ann Pharmacother 2005; 39: 1693-9 (Pubitemid 41393129)
10. Herbert JM, Augereau JM, Gleye J, Maffrand JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 1990; 172: 993-9
11. Chao MD, Chen IS, Cheng JT. Inhibition of protein kinase C translocation from cytosol to membrane by chelerythrine. Planta Med 1998; 64: 662-3
12. Chmura SJ, Dolan ME, Cha A, Mauceri HJ, Kufe DW, Weichselbaum RR. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res 2000; 6: 737-42 (Pubitemid 30111501)
13. Ulm AH, Miller F. An operation to produce experimental reversible hydronephrosis in dogs. J Urol 1962; 88: 337-41
14. Yamashita N, Baxter GF, Yellon DM. Exercise directly enhances myocardial tolerance to ischaemia-reperfusion injury in the rat through a protein kinase C mediated mechanism. Heart 2001; 85: 331-6 (Pubitemid 32973571)
15. Aoki Y, Mori S, Kitajima K et al. Id2 haploinsufficiency in mice leads to congenital hydronephrosis resembling that in humans. Genes Cells 2004; 9: 1287-96 (Pubitemid 39618541)
16. Tsuchida S, Matsusaka T, Chen X et al. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest 1998; 1 01: 755-60 (Pubitemid 28096071)
17. Hsieh YC, Chen YH, Jao HC, Hsu HK, Huang LJ, Hsu C. Role of cAMP-response element-binding protein phosphorylation in hepatic apoptosis under protein kinase C alpha suppression during sepsis. Shock 2005; 24: 357-63 (Pubitemid 41416522)
18. Chuang YH, Chuang WL, Huang SP, Huang CH. Over-expression of apoptosis-related proteins contributes to muscular damage in the obstructed ureter of the rat. BJU Int 2002; 89: 106-12 (Pubitemid 34117777)
19. Chuang YH, Chuang WL, Huang SP, Huang CH. Cyclooxygenase-2 inhibitor ameliorates ureteric damage in rats with obstructed uropathy. Eur J Pharmacol 2007; 569: 126-37 (Pubitemid 47189560)
20. Chuang YH, Chuang WL, Huang SP, Liu CK, Huang CH. Inhibition of nuclear factor-kappa B (NF-kappaB) activation attenuates ureteric damage in obstructive uropathy. Pharmacol Res 2009; 60: 347-57
21. Klahr S. Obstructive nephropathy. Kidney Int 1998; 54: 286-300 (Pubitemid 28288050)
22. Bascands JL, Schanstra JP. Obstructive nephropathy: insights from genetically engineered animals. Kidney Int 2005; 68: 925-37 (Pubitemid 43246409)
23. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-92 (Pubitemid 24333194)
24. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-8 (Pubitemid 30408720)
25. Border WA, Noble NA. TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int 1997; 51: 1388-96 (Pubitemid 27239888)
26. Kawada N, Moriyama T, Ando A et al. Increased oxidative stress in mouse kidneys with unilateral ureteral obstruction. K idney Int 1999; 5 6: 1004-13 (Pubitemid 29411727)
27. Roberts AB, McCune BK, Sporn MB. TGF-beta: regulation of extracellular matrix. Kidney Int 1992; 41: 557-9
28. O'Flaherty JT, Chadwell BA, Kearns MW, Sergeant S, Daniel LW. Protein kinases C translocation responses to low concentrations of arachidonic acid. J Biol Chem 2001; 276: 24743-50
29. Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. P roc Natl Acad Sci U S A 1989; 86: 2863-7 (Pubitemid 19112640)
30. Pushpanjali P, Ramaiah KV. PKC activation contributes to caspase-mediated eIF2alpha phosphorylation and cell death. Biochim Biophys Acta 2010; 1800: 518-25
31. Ha H, Yu MR, Lee HB. High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int 2001; 59: 463-70 (Pubitemid 32157911)
32. Docherty NG, O'Sullivan OE, Healy DA, Fitzpatrick JM, Watson RW. Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am J Physiol Renal Physiol 2006; 290: F4-13
33. Nowak G. Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem 2002; 277: 43377-88 (Pubitemid 35285726)
34. Arima S, Kohagura K, Xu HL et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 2004; 43: 352-7 (Pubitemid 38174138)
35. Xie C, Wang DH. Ablation of transient receptor potential vanilloid 1 abolishes endothelin-induced increases in afferent renal nerve activity: mechanisms and functional significance. Hypertension 2009; 54: 1298-305
36. Kirton CA, Loutzenhiser R. Alterations in basal protein kinase C activity modulate renal afferent arteriolar myogenic reactivity. Am J Physiol 1998; 275: H467-75
37. Nagareddy PR, Soliman H, Lin G et al. Selective inhibition of protein kinase C beta(2) attenuates inducible nitric oxide synthase-mediated cardiovascular abnormalities in streptozotocin-induced diabetic rats. Diabetes 2009; 58: 2355-64
38. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007; 55: 498-510 (Pubitemid 46962309)
39. Wei L, Sun D, Yin Z et al. A PKC-beta inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats. Apoptosis 2010; 15: 488-98
40. Yang JI, Yoon JH, Bang YJ et al. Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 2010; 298: G126-32